Davidov M E, Becker F E, Hollifield J W
Am J Med. 1987 Mar 20;82(3A):48-51. doi: 10.1016/0002-9343(87)90132-x.
Determinations of serum magnesium and potassium levels and blood pressure were made in 40 hypertensive patients in whom daily therapy with 50 mg of hydrochlorothiazide plus potassium supplements was switched to a once-daily regimen of 50 mg of hydrochlorothiazide plus 75 mg of triamterene (Maxzide). Patients showed no clinically significant changes in blood pressure or in serum magnesium or serum potassium values following the switch. It is concluded that therapy in patients receiving hydrochlorothiazide and up to 60 meq of potassium can be safely switched to Maxzide without adversely affecting serum magnesium levels, serum potassium levels, or blood pressure control.
对40例高血压患者进行了血清镁、钾水平及血压测定。这些患者原本接受每日50毫克氢氯噻嗪加钾补充剂的治疗，现改为每日一次服用50毫克氢氯噻嗪加75毫克氨苯蝶啶（Maxzide）的治疗方案。换药后，患者的血压、血清镁或血清钾值均未出现临床显著变化。结论是，接受氢氯噻嗪和高达60毫当量钾治疗的患者，可安全地改用Maxzide，而不会对血清镁水平、血清钾水平或血压控制产生不利影响。
